The resulting metabolic benefits of TRE may stem from its ability to reduce the duration of hyperglycemia and hyperinsulinemia, limiting the activation of insulin and insulin-like growth factor (IGF) pathways that are implicated in cancer development [111]. The gene discussed is IGF1; the disease is Hyperinsulinemia.